arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Full program

Saturday 09 Mar

13:00

Opening

Lessons to be learned from national and international research infrastructures

13:05

Dutch T1 CRC working group

13:12

French GRECCAR Study Group

13:19

Centre for trials research, Cancer trials

13:26

Danish Colorectal Cancer Group

13:33

Dutch Colorectal Cancer Group

13:40

Italian Intergroup structure and projects

13:47

German AIO group

13:54

Spanish TTD Group

14:01

Portuguese GICD study group

14:08

EORTC GI group

14:15

Discussion

14:30

Break

15:00

Plenary sponsored symposium

Discussing areas of controversy

16:00

In locoregional treatment of rectal cancer

16:25

In locoregional treatment of colon cancer

16:50

In local treatments of metastases: Surgery, Interventional radiology, Radiotherapy

17:35

In systemic treatment

18:00

DCCG lecture - Colon cancer: What is the best approach to understand the disease?

19:00

Welcome reception

Sunday 10 Mar

Session 1: Challenges in screen detected early cancers

08:15

Prediction models for lymph node metastases

08:35

Evaluation of the resection margin - is 1mm sufficient?

08:55

What is coming next in the prediction of lymph node metastases

09:15

Discussion

Session 2: What’s new in diagnostic imaging – and what are the therapeutic consequences?

09:30

Locoregional staging of colon and rectal cancer

09:50

Imaging modalities for liver metastases

10:10

New diagnostic tools: Radiomics, “deep learning” – really helpful?

10:30

Discussion

10:30 - 16:00 Gastroenterology parallel program

For the program, please click on below link

Gastroenterology parallel program

10:45

Break

Session 3: Controversies in preoperative treatment

11:15

Difference between cCR after CRT for advanced rectal cancer and aiming for cCR with CRT in early rectal cancer

11:35

Is chemotherapy going to replace radiotherapy in rectal cancer?

11:55

Deciding on further local treatment after induction therapy for local and metastatic disease; value and timing of re-staging modalities

12:15

Discussion

12:30

Lunch & Poster viewing

CRC Group Meetings / Trial Meetings / Consensus or Guideline initiatives

12:45

InterAACT: A global initiative in anal cancer

Translational Research: From bench to bedside and back

12:45

From Tissue towards Liquid biopsy: current status

Prof. Marc Peeters

University of Antwerp, Belgium

13:00

The serrated pathway: implications for research

Prof Iris Nagtegaal

Radboud University, Nijmegen, The Netherlands

13:15

Organoids from peritoneal metastases: towards personalized treatment

Prof Onno Kranenburg

University Medical Center Utrecht, The Netherlands

13:30

Selected abstract to be announced

12:45

Plenary Sponsored symposium

Session 4: Case discussion with expert panel

14:00

Case on the edge of liver surgery for mCRC

14:30

Case on the edge of multimodality treatment of mCRC

Session 5: Translational research: From markers to decisions

15:00

Clinical implications of “liquid” markers (ctDNA) for treatment selection and response evaluation

15:20

Clinical implications of tissue-based markers (CMS and others)

15:40

Organoids to assess treatment response

16:00

Break

Session 6: What’s new in diagnostic and therapeutic endoscopy?

16:30

State of the art optical diagnosis of polyps

16:50

Endoscopic and surgical techniques for local excision in rectal cancer, what should we do?

17:10

Endoscopic and hybrid techniques for local excision of colon cancer

17:30

Discussion

19:00

Dinner event

Monday 11 Mar

Session 7: Future of primary rectal cancer treatment

08:15

Role of external boost and brachytherapy in rectal cancer

08:35

Challenges in rectal cancer surgery; which problems have to be solved?

08:55

Locally recurrent rectal cancer; multimodality approach

09:15

Discussion

09.30 – 15.45 Interactive radiology workshops

For the program, please click on below link

Interactive radiology workshops

Session 8: Systemic therapy in the metastatic setting – state of the art and future

09:30

Targeting RAS mutated tumors

09:50

Prognostic/predictive value of molecular and clinical factors: What makes the difference?

10:10

Optimal strategy to convert CRCLM into resectable disease; CAIRO5

10:30

Discussion

10:45

Break

Session 9: Colorectal cancer and the immune system

11:15

What are the new drugs in the field of immunotherapy?

11:35

What are the diagnostic tools and novel concepts of cancer evolution?

11:55

What are the effects that are interfering with local or current treatments?

12:15

Discussion

12:45

Lunch & Poster viewing

12:45

Plenary Sponsored Symposium

CRC Group Meetings / Trial Meetings / Consensus or Guideline initiatives

12:45

Prospective national CRC cohort (PLCRC)

12:45

Presentation of CIREL and CIEMAR registries

12:45

Best abstracts

Session 10: Genetics

14:00

Update: the genetic differential diagnosis of polyposis and CRC

14:20

Predicting CRC risk: from tumor syndromes genes to polygenic risk scores

14:40

Chemoprevention and vaccines for hereditary CRC

15:00

Discussion

15:15

Break

Session 11: Curative treatment of metastases

15:45

Controversies in loco-regional therapy of peritoneal metastases: What is really needed?

16:05

Liver-directed therapies (Hepatic arterial infusion, SIRT): What to use when?

16:25

Spectrum of treatments for lung metastases: SBRT, RFA, resection or no local therapy at all?

16:45

Discussion

17:00

Closing and drinks